Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Azitra, Inc. (AZTR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, which are central to understanding this clinical stage biopharmaceutical issuer focused on precision dermatology. Through its Forms 8-K, S-1, DEF 14A and related documents, Azitra outlines the status of its live biotherapeutic and engineered protein programs, capital structure, and stock exchange compliance.
Filings such as Form 8-K detail material events, including notices from NYSE American regarding non-compliance with minimum stockholders’ equity requirements and subsequent acceptance of Azitra’s plan to regain compliance by April 1, 2027. Other 8-K reports describe private placement transactions involving common stock, pre-funded warrants, and common stock purchase warrants, as well as placement agency agreements and registration rights agreements tied to these financings. Additional 8-Ks furnish quarterly financial results and discuss reverse stock split actions implemented through amendments to the company’s certificate of incorporation.
Azitra’s Form S-1 registration statements provide further insight into its equity line of credit with Alumni Capital LP, the potential issuance of ELOC shares and warrants, and the resale registration of securities issued in private transactions. These documents explain how the company may raise capital over time and the number and types of securities that may be issued. The DEF 14A definitive proxy statement for a Special Meeting of Stockholders describes proposals to approve share issuances under NYSE American rules, including shares underlying warrants issued pursuant to a securities purchase agreement.
On this page, Stock Titan pairs Azitra’s real-time EDGAR filings feed with AI-powered summaries that help explain the significance of key documents. Users can quickly understand stock issuance proposals, listing standard issues, reverse stock splits, and financing structures without reading every page of each filing. Access to forms related to insider or major holder transactions, when filed, complements this view by showing how ownership and capital structure evolve as Azitra advances its ATR-12, ATR-04, and ATR-01 programs.
Azitra, Inc. President and CEO Francisco D. Salva reported significant insider purchases of derivative securities. On March 18, 2026, he bought 500 shares of Series A Convertible Non-Redeemable Preferred Stock, which has a stated value of $1,000 per share and automatically converts into 8,128.1 shares of common stock per preferred share once specific stockholder approvals and a charter amendment are obtained.
He also purchased 4,064,050 Series B Warrants and 4,064,050 Series C Warrants, each exercisable for common stock at $0.123 per share. The Series B Warrants become exercisable upon stockholder approval and expire 18 months afterward, while the Series C Warrants become exercisable upon stockholder approval and terminate 30 days after Azitra publicly announces data from its planned human cosmetic study using filaggrin technology.
Azitra, Inc. received a notice from NYSE American that it is not in compliance with the exchange’s continued listing standard requiring stockholders’ equity of at least $6.0 million for companies with losses in their five most recent fiscal years. As of December 31, 2025, Azitra reported stockholders’ equity of $3.8 million and losses over that five-year period. The exchange has accepted a previously submitted plan giving Azitra until April 1, 2027 to regain compliance with both the $4.0 million and $6.0 million equity thresholds, during which the company must provide quarterly progress updates. If it fails to make sufficient progress or meet these standards by the deadline, NYSE American staff may initiate delisting proceedings, though Azitra could appeal. The company also highlights that its latest audited financial statements contain an auditor’s paragraph expressing substantial doubt about its ability to continue as a going concern. Trading of Azitra’s common stock continues on NYSE American for now.
Azitra, Inc. canceled its 2026 special meeting of stockholders. The meeting was originally scheduled for February 6, 2026 and adjourned to March 6, 2026 after the company previously lacked a quorum. On March 4, 2026, Azitra withdrew the proposals described in its definitive proxy statement and decided not to reconvene the adjourned meeting.
Azitra is a clinical stage biopharmaceutical company focused on precision dermatology. Its lead program, ATR-12, is an engineered strain of S. epidermidis for Netherton syndrome and includes a Phase 1b trial in adult patients. A second program, ATR-04, targets EGFR inhibitor–associated rash and has FDA Fast Track designation and an open IND.
Azitra, Inc. reported full-year 2025 results and highlighted progress across its dermatology pipeline. For the year ended December 31, 2025, the company generated no revenue versus $7,500 in 2024 and recorded a net loss of $10.96M, wider than $8.97M a year earlier.
Research and development expenses were $4.8M and general and administrative expenses were $6.1M, both roughly flat year over year. Cash and cash equivalents were $2.07M at December 31, 2025, down from $4.55M at the prior year-end, after completing $8.5M of financings during 2025.
Clinically, Azitra advanced ATR-12, its lead program for Netherton syndrome, reporting promising Phase 1b safety data and guiding to topline results in the second half of 2026. ATR-04 for EGFR inhibitor–associated rash dosed its first Phase 1/2 patient, with initial cohort data expected around mid-2026, while ATR-01 for ichthyosis vulgaris reported positive preclinical data and continues IND-enabling work into 2026.
Azitra, Inc. files its annual report describing an early-stage biopharmaceutical business focused on precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary microbial library of about 1,500 bacterial strains supported by artificial intelligence and licensed genetic engineering technology.
Its lead programs are ATR-12 for Netherton syndrome, ATR-04 for epidermal growth factor receptor inhibitor–associated rash, and ATR-01 for ichthyosis vulgaris, all using modified Staphylococcus epidermidis. Azitra highlights academic and technology partnerships, an IP portfolio including U.S. and foreign patents, and extensive regulatory, financing, clinical, competitive, and operational risks typical for an early-stage biotech without commercial products.
Azitra, Inc. postponed its special stockholder meeting after too few shares were represented to reach a quorum and will reconvene the meeting virtually on March 6, 2026.
Only about 13% of outstanding shares were represented, below the required 33 1/3%. Stockholders will still vote on approving the issuance of more than 19.99% of outstanding common stock under a Securities Purchase Agreement with Alumni Capital LP and on a proposal to further adjourn the meeting if needed. Shareholders who already voted and do not change their instructions do not need to act again.
Azitra, Inc. has called a virtual special stockholder meeting on February 6, 2026 to vote on issuing more than 19.99% of its outstanding common stock under NYSE American rules. The key item is approval of common shares issuable upon exercise of warrants held by Alumni Capital LP under a November 24, 2025 securities purchase agreement. Azitra has already raised about $1.5 million in gross proceeds from this private placement and could receive an additional $1.5 million in gross proceeds if the Alumni Capital warrants are exercised for cash in full, plus about $75,000 if placement agent warrants are fully exercised.
The company states that existing cash and short-term investments, including recent financings, will not fund operating and capital needs for the next twelve months. If it cannot raise additional capital in the very near term, Azitra warns it may need to delay or cut development efforts, reduce marketing, or potentially cease operations and seek protection under the United States Bankruptcy Code. Approval of the proposal would also eliminate an exchange cap limiting issuances to 19.99% and would increase dilution and potential share price volatility for current stockholders. A second proposal would allow adjournment of the meeting to solicit additional proxies if needed.
Azitra, Inc. is asking stockholders to approve the issuance of more than 19.99% of its outstanding common stock, through shares underlying warrants issued to Alumni Capital LP under a November 24, 2025 securities purchase agreement. This approval is required under NYSE American rules to lift a 19.99% cap tied to the private placement.
The company has already closed the offering, selling 535,759 shares and issuing pre-funded and common stock purchase warrants at an offering price of $0.32, raising approximately $1.5 million in gross proceeds. If stockholders approve Proposal 1 and Alumni Capital exercises all its warrants for cash, Azitra would receive an additional $1.5 million, increasing total gross proceeds from the transaction to about $3.0 million. The Board warns that without this approval and additional capital, existing cash will not fund operations for the next twelve months and the company may need to sharply cut programs or potentially seek bankruptcy protection. A second proposal would allow adjournment of the special meeting to solicit more proxies if needed.
Azitra, Inc. reported an insider equity award for a senior executive and director. On 12/19/2025, the reporting person was granted stock options to acquire 23,724 shares of common stock at an exercise price of $0.2968 per share. These options expire on 12/19/2035.
According to the vesting terms, 25% of the common stock underlying the option vests on the grant date, with the remaining balance vesting in equal monthly installments over the following 36 months of continuous service. After this grant, the reporting person beneficially owns 23,724 derivative securities, held directly.
Azitra, Inc. reported an equity award to its President, CEO and director, Francisco D. Salva. On 12/19/2025, he received a stock option to buy 59,309 shares of Azitra common stock at an exercise price of $0.2968 per share. The option expires on 12/19/2035.
According to the vesting terms, 25% of the shares vest on the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months of continuous service. Following this grant, 59,309 derivative securities are beneficially owned directly.